These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8170219)

  • 1. [Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis].
    Laguna del Estal P; Calabrese S; Zabala JA; Martín T
    Med Clin (Barc); 1994 Feb; 102(7):276-7. PubMed ID: 8170219
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 3. Antimony-induced cerebellar ataxia.
    Khalil EA; Ahmed AE; Musa AM; Hussein MH
    Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Agranulocytosis caused by glucantime (N-methylglucamine antimoniate) during treatment of kala-azar].
    Gutiérrez Rodero F; Moya Jeromini I; Ortiz de la Tabla Ducasse V; Pozuelo González A
    Med Clin (Barc); 1985 May; 84(20):840. PubMed ID: 4033266
    [No Abstract]   [Full Text] [Related]  

  • 5. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of visceral leishmaniasis in patients with antimonials: is there a maximal dose?].
    Llorens Soriano P; Vicente Ull R; Paricio Blasco A; Cervera Juan A; Rubio Rodrigo MJ
    An Med Interna; 1999 Nov; 16(11):602. PubMed ID: 10638007
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
    Colakoglu M; Fidan Yaylali G; Yalcin Colakoglu N; Yilmaz M
    Scand J Infect Dis; 2006; 38(3):208-10. PubMed ID: 16500783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PKDL--a drug related phenomenon?
    Croft SL
    Indian J Med Res; 2008 Jul; 128(1):10-1. PubMed ID: 18820352
    [No Abstract]   [Full Text] [Related]  

  • 9. [Agranulocytosis caused by glucantime in the treatment of kala-azar].
    Gutiérrez Rodero F
    Med Clin (Barc); 1986 Mar; 86(10):437. PubMed ID: 3713304
    [No Abstract]   [Full Text] [Related]  

  • 10. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
    Valencia ME; Laguna F; González Lahoz J
    An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
    Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
    Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
    Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
    Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conduction defect following pentavalent antimony therapy in visceral leishmaniasis.
    Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Islam F
    Trop Doct; 1997 Jan; 27(1):59-61. PubMed ID: 9030031
    [No Abstract]   [Full Text] [Related]  

  • 15. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents.
    Kuryshev YA; Wang L; Wible BA; Wan X; Ficker E
    Mol Pharmacol; 2006 Apr; 69(4):1216-25. PubMed ID: 16418337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium stibogluconate and polymorphic ventricular tachycardia.
    Baranwal AK; Mandal RN; Singh R; Singhi SC
    Indian J Pediatr; 2005 Mar; 72(3):269. PubMed ID: 15812130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium stibogluconate.
    Shrestha NK
    Clin Infect Dis; 2006 Nov; 43(10):1371-2. PubMed ID: 17051510
    [No Abstract]   [Full Text] [Related]  

  • 18. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
    Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
    Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does antimony therapy cause bleeding in kala-azar patients and why?
    Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
    Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.